# Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

> **NCT05276713** · — · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucidinostat

## Key facts

- **NCT ID:** NCT05276713
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-10
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276713, "Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05276713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*